APO E genotyping

PreclinicalBiologic

CCentre Hospitalier Universitaire de Nīmes

APO E genotyping is one of 3 biologic programs targeting Hemosiderosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemosiderosisActive, not recruiting

HemosiderosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Hemosiderosis

#DrugCompanyPhaseTrials

Exjade

Novartis

Approved

3 2

Arava

Sanofi

Phase 2

1 3

APO E genotyping

CCentre Hospitalier Universitaire de Nīmes

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemosiderosis1 trial

Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis

Withdrawn·—·N/A·NCT02664571

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for APO E genotyping. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APO E genotyping compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APO E genotyping. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire de Nīmes company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentre Hospitalier Universitaire de Nīmes

APO E genotyping

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemosiderosis1 trial

References

Drug Info

Quick Facts

Related News